Wednesday, October 22, 2014 2:36:34 PM
"Pursuant to the Purchase Agreement and the Registration Rights Agreement, we have registered 23,418,172 shares of our common stock under the Securities Act, which includes the Commitment Shares and Initial Purchase Shares that have already been issued to Aspire Capital and 21,600,000 shares of common stock which we may issue to Aspire Capital. All 23,418,172 shares of common stock are being offered pursuant to this prospectus. Under the Purchase Agreement, we may have the right but not the obligation to issue more than the 23,418,172 shares of common stock included in this prospectus to Aspire Capital. Pursuant to the terms of NYSE MKT’s approval of our listing application for the shares to be issued under the Purchase Agreement, we may not issue more than 13,062,776 shares of our common stock pursuant to the Purchase Agreement, unless our stockholders approve the transaction contemplated by the Purchase Agreement. We may, but we are under no obligation to, request our stockholders to approve the transaction contemplated by the Purchase Agreement.
On October 20, 2014, the conditions necessary for purchases under the Purchase Agreement to commence were satisfied. On any trading day on which the closing sale price of our common stock is not less than the Floor Price ($0.44, the closing sale price of our shares on the business day before we entered into the Purchase Agreement), we have the right, in our sole discretion, to present Aspire Capital with a Purchase Notice, directing Aspire Capital (as principal) to purchase up to 150,000 shares of our common stock per business day, up to an additional $9.5 million of our common stock in the aggregate at a Purchase Price calculated by reference to the prevailing market price of our common stock over the preceding 10-business day period (as more specifically described below); however, no sale pursuant to a Purchase Notice may exceed $500,000 per trading day.
In addition, on any date on which we submit a Purchase Notice to Aspire Capital for 150,000 Purchase Shares and out stock price is not less than the Floor Price ($0.44, the closing sale price of our shares on the business day before we entered into the Purchase Agreement), we also have the right, in our sole discretion, to present Aspire Capital with a VWAP Purchase Notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on NYSE MKT on the next trading day, subject to the VWAP Purchase Share Volume Maximum and the VWAP Minimum Price Threshold. The VWAP Purchase Price is calculated by reference to the prevailing market price of our common stock (as more specifically described below).
The Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where the closing sale price of our common stock is less than the Floor Price ($0.44, the closing sale price of our shares on the business day before we entered into the Purchase Agreement). The Floor Price will be $0.20 per share of Common Stock, if our stockholders approve the transaction contemplated by the Purchase Agreement. We may, but we are under no obligation to, request our stockholders to approve the transaction contemplated by the Purchase Agreement. There are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales of our common stock to Aspire Capital. Aspire Capital has no right to require any sales by us, but is obligated to make purchases from us as we direct in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. The Purchase Agreement may be terminated by us at any time, at our discretion, without any penalty or cost to us.
Purchase of Shares Under The Common Stock Purchase Agreement
Under the common stock Purchase Agreement, on any trading day selected by us on which the closing sale price of our common stock exceeds the Floor Price, we may direct Aspire Capital to purchase up to 150,000 shares of our common stock per trading day. The Purchase Price of such shares is equal to the lesser of:
· the lowest sale price of our common stock on the purchase date; or
· the arithmetic average of the three lowest closing sale prices for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date."
Recent IBIO News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/31/2025 10:13:52 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/31/2025 10:11:15 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/30/2025 11:38:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2025 09:34:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2025 09:34:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2025 09:33:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2025 09:30:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2025 09:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 12:55:49 PM
- iBio Announces New Investments from Board Members and Officers • GlobeNewswire Inc. • 01/13/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 12:47:07 PM
- iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio • GlobeNewswire Inc. • 01/07/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2025 12:36:39 PM
- iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio • GlobeNewswire Inc. • 01/02/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2024 10:07:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2024 10:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2024 09:34:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2024 09:33:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2024 09:32:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/25/2024 01:30:10 PM
- iBio Strengthens Board with Appointment of Two New Independent Directors • GlobeNewswire Inc. • 11/25/2024 01:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/15/2024 01:47:49 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 09:48:52 PM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM
UAV Corp. Retains Legal Counsel to Address Legacy Debt from HTTI Era; 500 Million Authorized Shares Confirmed - UAV Corp. Delivers on Strategic Commitments • UMAV • Jan 31, 2025 1:30 PM